Objective: To study the concurrent and construct validity and test-retest reliability in the practice setting of an outcome measure for myasthenia gravis (MG).
tation. The investigators at each center have special expertise in MG management. Patients over 17 years of age with a clinical diagnosis of MG were recruited for the study if the treating physician predicted that they would be seen back for follow-up within 6 months. Written informed consent was obtained for each patient enrolled. The diagnosis of MG was made by the MG specialists at each center, and was almost always confirmed by serologic and electrodiagnostic testing.
Prior to the study, the neck flexion test item of the original MGC was modified to include neck extension testing (worse score recorded). Also, physicians were asked to record the duration until development of ptosis or dysconjugate gaze to see if the time required for these 2 test items could be shortened. After learning that Ͻ1% of ocular score times were between 46 and 60 seconds, the ocular test items were modified so that 45 seconds was the maximum duration of testing.
At the initial visit, the following data were recorded: demographic information, disease characteristics (e.g., duration, antibody status, Myasthenia Gravis Foundation of America [MGFA] class), MGC, and the Choose 2 component of the MGC. The Choose 2 form was administered by the physician, who asked the patient which 2 of 10 listed MG symptoms were considered by the patient to be most important to treat. A Choose 2 subscore was derived from the corresponding MGC scores of the patient's 2 chosen items. Investigators at each site chose to also include either the MG-manual muscle test (MG-MMT) or MG-activities of daily living (MG-ADL) as part of their patient assessment at each visit. 13, 15 A gestalt impression of change was determined by the physician at the second visit, based on their overall assessment of the patient without considering change in any of these MG scale scores. The 15-item myasthenia gravis quality of life scale (MG-QOL15) was completed by the patient at each study visit. 4 Patients were not instructed to omit pyridostigmine prior to their visits.
Test-retest reliability testing of the MGC was performed on 38 patients at 1 site (University of Virginia) from October 2008 to March 2009, by having the patient evaluated on the same day by one of the authors (T.M.B.) and also by a second physician, often a neurology resident or clinical neurophysiology fellow.
Concurrent validity was assessed by analyzing the correlation of the MGC scores with scores of other MG-specific outcome measures at visit 1 and visit 2. To assess longitudinal construct validity, we determined the sensitivity and specificity of the MGC for detecting clinical improvement. Because there is no gold standard for clinical improvement in MG and because every outcome measure has limitations, we compared the changes in MGC scores with several outcome measures, alone and in combination.
Test-retest reliability was estimated from the reliability coefficient and the 95% confidence intervals given in Fleis. 18 Concurrent validity between scales at each visit was estimated from the Pearson and Spearman correlation coefficients. In all cases, these correlation estimates were nearly equal, and all the correlation coefficients presented in this article are Pearson correlations. For each definition of a gold standard for clinical improvement, sensitivity and specificity were estimated using standard formulas. 19 Receiver operating characteristic (ROC) curves were used to assess the sensitivity and specificity corresponding to different cutoffs for the MGC.
RESULTS Test-retest reliability. A total of 38 patients with MG were evaluated independently on the same day by 2 neurologists (T.M.B. and another), who were blinded to the results of the other evaluation. The order of evaluators varied depending on the situation; often the other evaluator (e.g., clinical neurophysiology fellow) performed the first evaluation followed by T.M.B., but other times T.M.B. evaluated first followed by a resident or fellow. The mean MGC score at the first assessment was 4.9 (SD ϭ 7.1; range ϭ 0 -35). The MGC score never differed by more than 4 points between evaluators; it Severe weakness ϭ 5 a Moderate weakness for neck and limb items should be construed as weakness that equals roughly 50% Ϯ15% of expected normal strength. Any weakness milder than that would be mild and any weakness more severe than that would be classified as severe.
was within 2 points in 92% of patients, and within 3 points in 95%. The test-retest reliability coefficient was 98%, with a lower 95% confidence interval [CI] of 97%, indicating excellent test-retest reliability. Score differences for individual test items were most frequent for ptosis (6/38) and double vision (6/38), followed by neck strength (3/38) testing. Breakdown by current MGFA Class at visit 1 is as follows: 22% Class I (ocular), 41% Class II (mild, generalized), 19% Class III (moderate, generalized), 3% Class IV (severe, generalized). A total of 15% of patients were in remission (Class 0) at visit 1. None were intubated and ventilated (Class V) at visit 1, but 14.3% had experienced at least 1 prior episode of myasthenic crisis. At visit 2, 24% were Class I, 42% Class II, 13% Class III, 0% Class IV, and Class V, and 20% were in remission. A total of 78% of patients were acetylcholine receptor antibody positive (AChRϩ) and 7% were muscle specific tyrosine kinase positive (MuSKϩ). A total of 10% of patients had negative serology for at least AChR (often both AChR and MuSK). Serologic status was unknown for 5%. Of the 175 subjects, 142 (82%) were follow-up outpatients, 23 (13%) were newly diagnosed, and 8 (5%) were hospitalized for MG at the time of the evaluation. A total of 110/175 (63%) patients were taking pyridostigmine at the time of their first visit.
The mean, median, SD, and range of MG scale scores for both visits are listed in table 2. The total MGC scores showed excellent concurrent validity with other MG-specific scales. At visit 1, the total MGC score had a correlation of 0.68 (95% CI 0.59 -0.75) with the MG-QOL15 total score, 0.85 (95% CI 0.77-0.90) with the MG-ADL total score, and 0.80 (95% CI 0.72-0.86) with the MG-MMT total score. Nearly identical correlations were observed at visit 2.
Responsiveness and longitudinal construct validity of the MGC were assessed by using different gold standards of clinical change (table 3). The figure 1 demonstrates the ROC curve for the MGC using the physician impression of improvement plus improvement in MG-QOL15 score (visit 2-visit 1) as the criterion for improvement. Analyses of sensitivities and specificities of the MGC revealed that a 3-point improvement in MGC score was optimal for signifying clinical improvement. Furthermore, a Ն3-point improvement in the MGC appears to be meaningful to most patients. For instance, of the 49 patients with a Ն3-point improvement in the MGC score (visit 2-visit 1), the mean improvement (i.e., decrease) in MG-QOL15 total score was 12.2 (SD ϭ 11.4), compared to a mean MG-QOL15 improvement of 2.5 (SD ϭ 8.7) among the 52 patients with an improvement in MGC of 0 to 2 points, and a mean MG-QOL15 worsening of 1.1 (SD ϭ 8.8) points among the 37 patients whose MGC score worsened (visit 2-visit 1). In addition, 44 (90%) of the 49 patients who had a Ն3-point improvement in the MGC had an improved MG-QOL15 score at visit 2. Using the physician impression of improvement plus improvement in the MG-QOL15 score as the gold standard for clinical improvement, the effect on sensitivity and specificity of different choices for cutoffs for the MGC, MG-ADL, and MG-MMT scores is shown in table 4. A 1-or 2-point drop in the MGC also provides high sensitivity with small sacrifices in specificity. The sensitivities and specificities for the MGC compare favorably with the MG-ADL and MG-MMT (table 4).
In the subgroup of patients with initial MGC scores of 5 or more, the sensitivity of a 3-point change in MGC was 94.6% (n ϭ 42) and the specificity was 80.0% (n ϭ 45). In the group with initial MGC score of 7 or more, the sensitivity was 100% and the specificity was 81%.
Analysis of the Choose 2 component of the MGC.
Eyelid droop (33%), double vision (36%), and trouble swallowing (36%) were the 3 most common domains selected by the patient as being most important during the Choose 2 component of the MGC. At each visit, the correlations for the MG-MMT, MG-ADL, and MG-QOL15 to the Choose 2 subscale score were lower than to the total MGC score. For all the gold standards of change listed in table 3, the Choose 2 component showed either lower sensitivity or lower specificity than the MGC total (data not shown). These results do not support the use of the Choose 2 component of the MGC over the total MGC score. DISCUSSION The notable attributes of the MGC include the following. 1) The test items were rigorously selected through a process that assessed item performance during 2 randomized, controlled trials involving Ͼ250 patients with MG. 3 2) The MGC covers the 10 important functional domains most frequently affected by MG.
3) The proportion of bulbar and respiratory items to total number of items (4/10) is appropriate given the clinical importance of these domains. 4) The test items are appropriately weighted. For example, a maximum score for worst respiratory status is worth more points than the maximum score for worst eyelid strength. 5) The MGC is easy to administer, taking less than 5 minutes to complete, without the need for any equipment. 6) The MGC is easy to interpret, taking less than 10 seconds to calculate a total score. Also, the assessment of each of the 10 test items provides immediate insight into the status of that particular functional domain. 7) The MGC is reliable, as evidenced by the results of our test-retest assessment. 8) The MGC demonstrates concurrent and longitudinal construct validity in the MG practice care setting, based on the results of this prospective study conducted on Ͼ150 patients at 11 centers (table 3, table 4 , figure) . 20 It should be noted that most of our patients were in good clinical condition at study entry, and, thus, changes in status between clinic visits were often small and sometimes even questionable. It is theoretically easier to validate an instrument that measures future clinical improvement of patients whose initial clinical status is poor (e.g., newly diagnosed patients and patients entering treatment trials), for which improvement following initiation of new treatment is likely and is often of high magnitude. In these situations even coarse instruments will identify improvement. The fact that the MGC demonstrated excellent longitudinal construct validity even in our practice-based setting provides further evidence of its sensitivity.
The sample enrolled in this study is likely representative of the overall population of patients with MG because it included consecutive patients seen for routine care at 11 centers. The 9 centers in the United States were located in 9 different states (4 East Coast, 4 Midwest, and 1 West Coast). The 2 centers in Europe were in Glasgow and Milan. Our sample population is similar in many characteristics to other cohorts of patients with MG and covered the spectrum of MG severity. For example, the serologic status, percentage of patients with previous crisis, and proportion of patients by MGFA Class were similar to reported cohorts said to be representative of MG. [21] [22] [23] [24] Also, the mean MG-ADL score at visit 1 in our cohort was similar to what it was for patients enrolled in the Aspreva MG trial. 13 However, overall severity in our cohort was probably less than that of patients with MG entering most clinical trials because of exclusion from those trials of patients with milder disease (e.g., ocular MG [MGFA Class I] or patients in remission). For example, the mean MG-MMT (6.3) and MG-ADL (4.9) scores in our patients were lower than in the recent Muscle Study Group trial of mycophenolate mofetil for generalized MG.
The MGC can be used in everyday practice and in clinical trials. For clinical trials, we propose that a 3-point fall in MGC score be the cutpoint to indicate clinical improvement. The 3-point threshold demonstrated acceptable test-retest reliability and offered the best trade-off in terms of sensitivity and specificity when compared with the various criteria chosen to signify clinical improvement. A 3-point improvement in MGC also appears to be meaningful to most patients, as evidenced by a mean improvement in MG-QOL15 score of Ͼ12 points for those patients who had a Ն3-point improvement in the MGC.
The MGC differs from most scales in that it is a hybrid of physician-reported and patient-reported test items. This combination, however, is especially appropriate for an MG outcome measure for 3 major reasons. 1) MG manifests with fluctuating and fatigable symptoms and signs, which consequently limits the utility of measuring disease status solely based on a "snapshot" examination. 2) Manifestations of MG are evident not only to the physician but also to the patient (and others), and thus patient-reported measures of symptoms must be considered in assessing disease severity. 3) Dysfunction in chewing and swallowing are almost certainly more evident to the patient than to the physician. It is not surprising that certain patient-reported test items perform better than their physician-reported examination counterparts and thus justify inclusion in the MGC.
A limitation of our study is the lack of a single gold standard for clinical change. On the other hand, if there had been a gold standard then there would have been less reason to develop the MGC in the first place. To overcome this limitation of no gold standard, we looked at the performance of the MGC using several different criteria of change, each of which has its own limitations. For example, one problem with using MG-MMT or MG-ADL to assess MGC responsiveness is that the MGC contains 4 test items from each the MG-MMT and the MG-ADL. However, it was not reasonable to remove these shared items for the validity analysis because each item represents a functional domain that often acts independently of the other domains. Thus, assessing correlations with scales stripped of shared test items would offer little insight into the performance of the MGC. Limitations in using the physician impression of change as a comparator included physician uncertainty, limited physician memory of patient status at visit 1, and the fact that in some cases different physicians saw the patient at the 2 visits. We settled on the physician impression of improvement plus improvement in the patient-derived MG-QOL15 score as our gold standard for clinical improvement, and placed the most weight on this comparator to assess the longitudinal validity of the MGC and to determine the optimal cutpoint for signifying clinical improvement.
